Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 18 results
Filters: Author is Eapen, Mary [Clear All Filters]
“Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.”, Lancet Haematol, 2022.
, “Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.”, Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2022.
, “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
, “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
, “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
, “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
, “Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.”, Blood, vol. 132, no. 13, pp. 1438-1451, 2018.
, “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
, “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
, “Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.”, Lancet Haematol, vol. 2, no. 9, pp. e367-75, 2015.
, “Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer.”, J Comp Eff Res, vol. 3, no. 2, pp. 135-44, 2014.
, “Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.”, Biol Blood Marrow Transplant, vol. 20, no. 10, pp. 1485-92, 2014.
, “One-unit versus two-unit cord-blood transplantation for hematologic cancers.”, N Engl J Med, vol. 371, no. 18, pp. 1685-94, 2014.
, “Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.”, Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
, “Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 18, no. 8, pp. 1265-72, 2012.
, “Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.”, Blood, vol. 118, no. 2, pp. 282-8, 2011.
, “Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network,”, Biol Blood Marrow Transplant, vol. 17, no. 3, pp. 291-9, 2011.
,